

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Peds Open Studies

Registry

COG-APEC14B1 Project: EveryChild - A Registry, Eligibility Screening, Biology and Outcome Study [Albert Kheradpour, MD](mailto:Albert.Kheradpour@ucsf.edu)
<https://clinicaltrials.gov/ct2/show/NCT02402244>

CNS

COG-ACNS0332 Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients [Albert Kheradpour, MD](mailto:Albert.Kheradpour@ucsf.edu)
<https://clinicaltrials.gov/ct2/show/NCT00392327>
ONLY Stratum A & B are OPEN to enrollment

COG-ACNS0831 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years [Albert Kheradpour, MD](mailto:Albert.Kheradpour@ucsf.edu)
<http://www.clinicaltrials.gov/ct2/show/NCT01096368>

Ewing's Sarcoma

COG-AEWS1221 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma [Albert Kheradpour, MD](mailto:Albert.Kheradpour@ucsf.edu)
<https://clinicaltrials.gov/ct2/show/NCT02306161>

Germ Cell

COG-A031102 A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors [Albert Kheradpour, MD](mailto:Albert.Kheradpour@ucsf.edu)
<https://clinicaltrials.gov/ct2/show/NCT02375204>

COG-AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors [Albert Kheradpour, MD](mailto:Albert.Kheradpour@ucsf.edu)
<https://clinicaltrials.gov/ct2/show/NCT03067181>

Hodgkin's Lymphoma

COG-AHOD1331 A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults [Albert Kheradpour, MD](mailto:Albert.Kheradpour@ucsf.edu)
<https://clinicaltrials.gov/ct2/show/NCT02166463>

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Peds Open Studies

Hodgkin's Lymphoma continued

COG-AHOD1721 Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical Trial Evaluation
<https://clinicaltrials.gov/ct2/show/NCT02927769> [Albert Kheradpour, MD](#)

Kidney

COG-AREN03B2 Renal Tumors Classification, Biology and Banking Study
<http://clinicaltrials.gov/ct2/show/NCT00898365> [Albert Kheradpour, MD](#)

Leukemia

COG-AALL05B1 A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
<http://clinicaltrials.gov/ct2/show/NCT00897325> [Albert Kheradpour, MD](#)

COG-AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia
<http://www.clinicaltrials.gov/ct2/show/NCT01142427> [Albert Kheradpour, MD](#)

COG-AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or localized B-Linage Lymphoblastic Lymphoma (B-LLy)
<https://clinicaltrials.gov/ct2/show/NCT01190930>
Low Risk Arms C & M are CLOSED to enrollment
Average Risk Post-Induction / Pre-Maintenance is CLOSED to enrollment [Albert Kheradpour, MD](#)

COG-AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
<https://clinicaltrials.gov/ct2/show/NCT02101853> [Albert Kheradpour, MD](#)

COG-AALL1521 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
<https://clinicaltrials.gov/ct2/show/NCT02723994> [Albert Kheradpour, MD](#)

COG-AALL15P1 A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
<https://clinicaltrials.gov/ct2/show/NCT02828358> [Albert Kheradpour, MD](#)

COG-AALL1631 International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
<https://clinicaltrials.gov/ct2/show/NCT03007147> [Albert Kheradpour, MD](#)

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Peds Open Studies

Leukemia – continued

COG-AAML1331	A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All Trans-Retinoic Acid https://clinicaltrials.gov/ct2/show/NCT02339740	Albert Kheradpour, MD
COG-AAML1421	A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML) https://clinicaltrials.gov/ct2/show/NCT02642965	Albert Kheradpour, MD
COG-AAML1531	Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome https://clinicaltrials.gov/ct2/show/NCT02521493	Albert Kheradpour, MD
COG-ACCL1333	A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) treated with Pegylated (PEG) L-asparaginase https://clinicaltrials.gov/ct2/show/NCT02369653	Albert Kheradpour, MD

Liver

COG-AHEP0731	Treatment of Children with All Stages of Hepatoblastoma http://clinicaltrials.gov/ct2/show/NCT00980460 ONLY Stratum 1 and 4 are OPEN to enrollment	Albert Kheradpour, MD
--------------	--	---------------------------------------

Lymphoma

COG-ALTE11C1	Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma https://clinicaltrials.gov/ct2/show/NCT01793233	Albert Kheradpour, MD
COG-ADV1621	A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051) https://clinicaltrials.gov/ct2/show/NCT02332668	Albert Kheradpour, MD

Neuroblastoma

COG-ANBL00B1	Neuroblastoma Biology Studies http://clinicaltrials.gov/ct2/show/NCT00904241	Albert Kheradpour, MD
COG-ANBL1232	Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma http://clinicaltrials.gov/ct2/show/NCT02176967	Albert Kheradpour, MD

Questions? 800-78-CANCER, 909-558-CANCER, or 909-558-4050
Peds Open Studies

Osteosarcoma

COG-AOST1421 A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC #764038, IND #4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
<https://clinicaltrials.gov/ct2/show/NCT02484443>
ONLY Stratum 1 is OPEN to enrollment [Albert Kheradpour, MD](#)

Rhabdomyosarcoma

COG-ARST1321 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC #737754, IND #118613)
<http://clinicaltrials.gov/ct2/show/NCT02180867>
ONLY Stratum 1 – Regimen A & B are OPEN to enrollment [Albert Kheradpour, MD](#)

Solid Tumors

COG-ADVL1621 A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
<https://clinicaltrials.gov/ct2/show/NCT02332668> [Albert Kheradpour, MD](#)

COG-ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
<https://clinicaltrials.gov/ct2/show/NCT02867592>
Only Stratum 1 is OPEN to enrollment [Albert Kheradpour, MD](#)

Stem Cell Transplant

NMDP-10-CBA A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
<http://www.clinicaltrials.gov/ct2/show/NCT01351545> [Albert Kheradpour, MD](#)

NMDP-RESEARCH DATABASE Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
<http://www.clinicaltrials.gov/ct2/show/NCT00495300> [Albert Kheradpour, MD](#)

NMDP-SAMPLE REPOSITORY Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries
<http://www.clinicaltrials.gov/ct2/show/NCT00495300> [Albert Kheradpour, MD](#)

Venous Thromboembolism

Pfizer-AFRAG-A001-201 (A6301094) A Three Month Prospective Open Label Study of Therapy With Fragmin® (Dalteparin Sodium Injection) in Children With Venous Thromboembolism With or Without Malignancies
<https://clinicaltrials.gov/ct2/show/NCT00952380> [Albert Kheradpour, MD](#)